Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01986166 · ClinicalTrials.gov registry record · Phase 1
A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS
A Phase 1 study of Neoplasms, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 9
- Study locations
NCT01986166: Completed Phase 1 study of Neoplasms, sponsored by Genentech.
NCT01986166 is a Phase 1 study of Neoplasms that has completed, run by Genentech. The registered enrollment target is 23 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01986166, a Phase 1 study of Neoplasms, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 9
- Study locations
Study Summary
This open-label, multicenter, global Phase Ib study will evaluate the safety, tolerability and pharmacokinetics of intravenous (IV) dosing of MEHD7945A in combination with oral dosing of cobimetinib in patients with locally advanced or metastatic solid tumors that carry a Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) mutation and for which standard therapies do not exist, have proven ineffective or intolerable or are considered inappropriate. The study comprises a dose-escalation (Stage 1) and an indication-specific cohort expansion stage (Stage 2).
Conditions Studied
Interventions
- DRUG Cobimetinib
- DRUG MEHD7945A
Study Locations (9)
California
- - San Francisco
Colorado
- - Denver
Connecticut
- - New Haven
Michigan
- - Detroit
Tennessee
- - Nashville
Texas
- - Dallas
Barcelona
- - Barcelona
Madrid
- - Madrid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-11 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
What the finished NCT01986166 record still lists
NCT01986166 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Cobimetinib is the first listed.
NCT01986166 lists 9 locations in 9 states (California, Colorado, Connecticut).
Frequently Asked Questions
What is clinical trial NCT01986166 about?
NCT01986166 is a clinical study titled "A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS". This open-label, multicenter, global Phase Ib study will evaluate the safety, tolerability and pharmacokinetics of intravenous (IV) dosing of MEHD7945A in combination with oral dosing of cobimetinib in patients with locally advanced or metastatic solid tumors that carry a Kirsten Rat Sarcoma Viral O...
What is the current status of trial NCT01986166?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2013-11. Estimated completion is 2016-01.
What conditions does trial NCT01986166 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT01986166?
The interventions under investigation include: Cobimetinib (DRUG), MEHD7945A (DRUG).
Who is sponsoring clinical trial NCT01986166?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01986166 being conducted?
This trial has 9 study locations across California, Colorado, Connecticut, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01986166's enrollment target sits among peer trials
23 142nd of 158 higher than 15 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia